Cyclacel Pharmaceuticals Inc (CYCC) - Total Liabilities
Based on the latest financial reports, Cyclacel Pharmaceuticals Inc (CYCC) has total liabilities worth $770.00 USD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Cyclacel Pharmaceuticals Inc operating cash flow efficiency to assess how effectively this company generates cash.
Cyclacel Pharmaceuticals Inc - Total Liabilities Trend (2000–2024)
This chart illustrates how Cyclacel Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Check CYCC financial resilience to evaluate the company's liquid asset resilience ratio.
Cyclacel Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Cyclacel Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cowell Development Tbk
JK:COWL
|
Indonesia | Rp2.57 Trillion |
|
Grainger PLC
LSE:GRI
|
UK | GBX1.73 Billion |
|
TCS Group Holdings Bhd
KLSE:0221
|
Malaysia | RM161.49 Million |
|
Spirent Communications plc
LSE:SPT
|
UK | GBX199.60 Million |
|
Sambhaav Media Limited
NSE:SAMBHAAV
|
India | Rs130.26 Million |
|
Smartlink Holdings Limited
NSE:SMARTLINK
|
India | Rs639.48 Million |
|
Solueta Co Ltd
KQ:154040
|
Korea | ₩31.52 Billion |
Liability Composition Analysis (2000–2024)
This chart breaks down Cyclacel Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see CYCC market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.77 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cyclacel Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cyclacel Pharmaceuticals Inc (2000–2024)
The table below shows the annual total liabilities of Cyclacel Pharmaceuticals Inc from 2000 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $6.27 Million | -23.54% |
| 2023-12-31 | $8.20 Million | +7.63% |
| 2022-12-31 | $7.62 Million | +39.94% |
| 2021-12-31 | $5.44 Million | +53.63% |
| 2020-12-31 | $3.54 Million | -1.88% |
| 2019-12-31 | $3.61 Million | -20.65% |
| 2018-12-31 | $4.55 Million | +7.41% |
| 2017-12-31 | $4.24 Million | -21.38% |
| 2016-12-31 | $5.39 Million | -9.11% |
| 2015-12-31 | $5.93 Million | -22.99% |
| 2014-12-31 | $7.70 Million | +2.69% |
| 2013-12-31 | $7.50 Million | -19.69% |
| 2012-12-31 | $9.34 Million | +43.66% |
| 2011-12-31 | $6.50 Million | -0.57% |
| 2010-12-31 | $6.54 Million | -33.47% |
| 2009-12-31 | $9.82 Million | -4.78% |
| 2008-12-31 | $10.31 Million | -42.51% |
| 2007-12-31 | $17.94 Million | +91.76% |
| 2006-12-31 | $9.36 Million | +36.76% |
| 2005-12-31 | $6.84 Million | -40.42% |
| 2004-12-31 | $11.48 Million | -86.22% |
| 2003-12-31 | $83.34 Million | +19.64% |
| 2002-12-31 | $69.66 Million | +14.22% |
| 2001-12-31 | $60.99 Million | +13.23% |
| 2000-12-31 | $53.86 Million | -- |
About Cyclacel Pharmaceuticals Inc
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer medicines based on cell cycle, transcriptional regulation, epigenetics, and mitosis control biology in the United States. Its lead product Plogosertib or plogo, a solid tumors and hematological malignancies, which is in Phase 1/2 clinical trial. The company was founded in 1996 and is headquartered in Kuala… Read more